Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2020 | Duvelisib in CAR T-cell therapy for CLL

Edmund Waller • 1 Sep 2020
EBMT 2020
Chronic Lymphocytic Leukemia Leukemia Duvelisib

Edmund Waller, MD, PhD, FACP, Division of Hematology/Oncology, Emory Clinic, Atlanta, GA, outlines the use and activity of duvelisib in CAR T-cell therapy for patients with chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Edmund Waller

Managing GvHD in patients undergoing SCT 1:12
Managing GvHD in patients undergoing SCT
Edmund Waller • 8 Sep 2023
Optimizing conditioning regimens in patients with AML undergoing alloSCT 1:46
Optimizing conditioning regimens in patients with AML undergoing alloSCT
Edmund Waller • 8 Sep 2023
Improving transplantation outcomes in patients with active AML: current approaches & future outlooks 2:09
Improving transplantation outcomes in patients with active AML: current approaches & future outlooks
Edmund Waller • 8 Sep 2023
PORTIA: tisagenlecleucel and pembrolizumab in R/R DLBCL 5:01
PORTIA: tisagenlecleucel and pembrolizumab in R/R DLBCL
Edmund Waller • 23 Aug 2020

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals